Best Infectious Diseases Companies in Florida, United States
The 43 best Infectious Diseases companies in Florida, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Romark.
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Infectious Diseases companies in Florida
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Romark Developer of therapeutics for infectious diseases | $116M | 113 mo ago | 128 | Marc Ayers CEO | — | — | — |
| 2 | X-VAX Technology Developer of virus-based vaccines for treating herpes | $56M | 85 mo ago | 12 | — | — | — | — |
| 3 | Lakewood-Amedex Developer of nano RNA gene silencing platform to develop targeted therapeutics for viral infections | $36M | 67 mo ago | 11 | Steve Parkinson CEO | WordPressMySQLPHP+20 | 148 patents Novel heterocyclic antimicrobial agents and bisphosphonate gel formulations for pharmaceuticals. | 2 launchs |
| 4 | Rapid Pathogen Screening Point-of-care diagnostic devices for infectious diseases and inflammatory conditions | $36M | 128 mo ago | 7 | — | — | 190 patents Rapid point‑of‑care pathogen detection via immunoassay and selective white‑cell lysis | — |
| 5 | Rational Vaccines Developer of live attenuated viral immunotherapeutic and prophylactic vaccine candidates 29Funding top 28%Moat top 38%Patents top 40%Innovation top 46% All 8 signals ▾Fundingtop 28% Moattop 38% Patentstop 40% Innovationtop 46% Talentbottom 49% Techbottom 42% Globalbottom 37% Marketbottom 25% Funding: Raised $30.6M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 9 patents rank vs industry peers · Fliar Intelligence Index 29/100 | $31M | 11 mo ago | 18 18 → 11 (-39%) | Agustin Fernandez Founder & CEO | WordPressMySQLPHP+17 | 9 patents Serology diagnostics for SARS‑CoV‑2 and viral‑vector vaccines against intracellular pathogens | — |
| 6 | Emmune Biotechnology startup developing novel HIV treatment and prevention solutions | $18M | 15 mo ago | 7 | Michael Alpert Co-Founder | — | 25 patents Engineered protein therapeutics and scaffolded vaccine antigens for immune modulation | — |
| 7 | NanoVir Developer of DNA-targeting therapeutics to treat HPV | $12M | 193 mo ago | — | Chris Fisher Co-Founder | — | 33 patents Targeted antiviral small molecules and polyamides for dsDNA viruses, especially HPV | — |
| 8 | PositiveID Corporation Developer of biological detection and diagnostics solutions | $11M | 163 mo ago | 30 | — | — | 4 patents Real-time wireless acetone gas detection using portable molecular sensor devices | — |
| 9 | AIM ImmunoTech Developer of drugs for various immune-related diseases and cancer | $10M | 84 mo ago | 185 | Thomas Equels CEO | WordPressMySQLPHP+16 | 100 patents RNA‑based antivirals and vaccines targeting post‑COVID syndromes and neuroinflammation | — |
| 10 | Halodine Manufacturer of nasal and oral antiseptic products for virus protection. | $2M | 68 mo ago | 8 | Kevin Stewart Co-Founder | — | — | — |
| 11 | Quick-Med Technologies Sustainable antimicrobial technologies for hygiene, infection control, and environmental sustainability | $2M | 64 mo ago | 3 | — | — | — | — |
| 12 | Aviana Molecular Technologies Point-of-care diagnostics company revolutionizing healthcare testing with mobile biosensor technology | $1M | 113 mo ago | 9 | Vanaja Ragavan Chief Executive Officer and Chairman | — | 81 patents Surface acoustic wave biosensor platforms for multiplexed point-of-care diagnostics. | — |
| 13 | Earth Science tech Developer of a medical device for detection of chlamydia | $1M | 46 mo ago | 3 | — | WordPressMySQLPHP+15 | — | — |
| 14 | NOVODX Developer of point-of-care diagnostic test for in-home and clinical applications | $1M | 17 mo ago | — | Nancy Kaufman CEO | — | — | — |
| 15 | Allora Diagnostics Developer of breath-based medical device for detecting urease-positive pathogens | $401K | 60 mo ago | — | David Joseph CEO | — | — | — |
| 16 | Hansen Pharmaceutical Developer of gaseous nitric oxide to treat infections caused by antibiotic-resistant bacteria | $200K | 140 mo ago | — | Jeffrey L Jensen Co-Founder | — | — | — |
| 17 | Thread Bioscience Provider of rapid point-of-care solutions for infectious disease diagnosis | $102K | 56 mo ago | 5 | Craig Serio CEO | — | — | — |
Top 12 Infectious Diseases companies in Florida
#1
Series B · Miami, Florida · founded 2015 · 18 employees$30.6Mraised▾
Developer of live attenuated viral immunotherapeutic and prophylactic vaccine candidates. The company focuses on combating diseases resulting from herpes simplex virus infections. It aims to reduce suffering of those infected and reduce the spread of the virus. The goal is to revolutionize the treatment, prevention, and diagnosis of herpes and related diseases.
- Sep 2025Grant (prize money)$266.6K
- Apr 2025Grant (prize money)$291.5K
- Jan 2025Grant (prize money)$1.3M
- Aug 2023Grant (prize money)$1.3M
#2
Funding Raised · Jupiter, Florida · founded 2013 · 7 employees$17.5Mraised▾
Biotechnology startup developing novel HIV treatment and prevention solutions. The company is focused on addressing the HIV pandemic through innovative approaches. Their primary solution, eCD4-Ig AAV, represents a novel method for combating HIV infection. The company's mission is centered around creating effective tools for both treating existing HIV infections and preventing new ones. They are dedicated to research and development in the field of biotechnology, specifically targeting infectious diseases. The company operates as a biotechnology firm, contributing to advancements in medical science and public health. Their work has a direct social impact by addressing a global health challenge.
- May 2025Grant (prize money)$300K
- Aug 2023Grant (prize money)$2.3M
- Jan 2023Grant (prize money)$300K
- Mar 2022Grant (prize money)$3.2M
#3
Seed · Boca Raton, Florida · founded 2022$1Mraised▾
Developer of point-of-care diagnostic test for in-home and clinical applications. The company uses reusable quantitative & qualitative meters to mirror clinical reference lab results for self testing at home OTC, and in clinics POC for a variety of diseases, including respiratory diseases, infectious diseases, and men's and women's health.
- Mar 2025Seed$200K
- Sep 2023Seed$1M
#4
Series E · Tampa, Florida · founded 1994 · 128 employees$116.1Mraised▾
Developer of therapeutics for infectious diseases The company has one commercialized product, Alinia (nitazoxanide), for diarrhea. The company's current pipeline includes one molecule NT-300 (nitazoxanide) for influenza and for RSV. Other compounds include RM-5061 (anti-infective) and RM-5038 and RM-5064 as broad-spectrum antiviral agents.
- Mar 2017Series E$13.8M
- Feb 2016Series D$10.7M
- Nov 2014Series D$10.8M
- Jun 2014Series D$15M
#5
Public · Sarasota, Florida · founded 2006 · 11 employees$36.2Mraised▾
Developer of nano RNA gene silencing platform to develop targeted therapeutics for viral infections. The company's lead nanoRNA product, Influ-RNA, is an anti-influenza agent. The company is also developing drugs and has lead candidates for pneumonia in cystic fibrosis patients, chronic wounds, chronic otitis media, and implant- and catheter-associated infections.
- Jan 2021Series C$24.1M
- Sep 2015Series C$6.6M
- Jun 2014Series C$5.5M
#6
Deadpooled · Jupiter, Florida · founded 2017 · 12 employees$56.5Mraised▾
Developer of virus-based vaccines for treating herpes. The vaccines also target other pathogens such as influenza, tuberculosis, and HIV. The company is developing the vaccine gD-2, which is a virus-based vaccine. Their platform enables the inserting of genes from other pathogens like the influenza virus.
- Jul 2019Series A$56.5M
- Sep 2016Seed$100K
#7
Series B · Sarasota, Florida · founded 2004 · 7 employees$35.6Mraised▾
Rapid Pathogen Screening develops, manufactures and commercializes point-of-care (POC) diagnostic tests. The company currently offers two products in the United States. AdenoPlus® is a CLIA-waived point-of-care product that detects all known serotypes of adenoviral conjunctivitis. InflammaDry® is an in-office test that detects MMP-9, an inflammatory marker that is consistently elevated in the tears of patients with dry eye disease. Outside the United States, the company also offers FebriDx®, a test that uses a fingerstick blood sample to identify and differentiate a clinically significant immune response to viral and/or bacterial acute febrile respiratory infection.
- Dec 2015Series B$1.8M
- Oct 2014Venture Debt$28M
- Jul 2013Series B$6.2M
- Jul 2013Series B$2.3M
#8
Public · Ocala, Florida · founded 1966 · 185 employees$10.1Mraised▾
Developer of drugs for various immune-related diseases and cancer. The company's products include Ampligen a developmental drug of a large macromolecular RNA molecule and Alferon N Injection for the treatment of refractory or recurrent external condylomata acuminate. The product is also being evaluated for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome. Also, developing drugs for the treatment of cancer.
- Aug 2019Post IPO$2.6M
- Sep 2018Post IPO$3.2M
- Apr 2018Post IPO$25.7K
- Feb 2017Post IPO$18.2K
#9
Deadpooled · Delray Beach, Florida · founded 2001 · 30 employees$10.9Mraised▾
Developer of biological detection and diagnostics solutions. The company focused on the development of microfluidic systems M-BAND (Microfluidic Bio-agent Autonomous Networked Detector) that analyzes air samples for the detection of biological airborne threats in the form of bacteria, viruses, and toxins.
- Jan 2013Series A$1.1M
- Aug 2011Series A$1.5M
- May 2011Series A$950K
- Mar 2011Series A$4.7M
#10
Funding Raised · Gainesville, Florida · founded 2003$11.9Mraised▾
Developer of DNA-targeting therapeutics to treat HPV. The company is designing chemicals that bind to specific viral DNA sequences and thereby disrupt viral DNA maintenance in infected cells dramatically reducing the viral DNA load of cells harboring the virus.
- Jul 2010Grant (prize money)$3M
- May 2008Grant (prize money)$2.9M
- Dec 2005Grant (prize money)$3M
- Jul 2004Grant (prize money)$2.9M
#11
Public · Doral, Florida · founded 2014 · 3 employees$1.2Mraised▾
Developer of a medical device for detection of chlamydia. The technology involves a non-invasive MSN-2 medical device (which is similar to a modern panty liner but with a special filter) to be worn for 4 consecutive hours, and the liner is then sent to the company and their accredited laboratories for testing using msn-2 medical device.
- Oct 2022Post IPO$674.2K
- Apr 2018Post IPO$497.6K
#12
Public · Gainesville, Florida · founded 1997 · 3 employees$2Mraised▾
Sustainable antimicrobial technologies for hygiene, infection control, and environmental sustainability. The company develops innovative, green antimicrobial technologies offering safety, efficacy, cost-effectiveness, durability, and sustainability. They provide services including treatment optimization, laboratory prototyping, regulatory guidance, microbiological efficacy testing, patent expertise, and market evaluations. Their technologies address consumer, industrial, and medical markets, focusing on antimicrobial stewardship and environmental responsibility. They offer surface antimicrobials, reducing water and cleaning product consumption. Their products are sold and distributed globally. The company focuses on scientific discovery and sustainable solutions for a better future.
- Apr 2021Grant (prize money)$256K
- Jul 2014Grant (prize money)$150K
- Jul 2013Grant (prize money)$150K
- May 2013Grant (prize money)$150K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding flat · growth falling
How research on Diagnostics in Florida is moving
A read on the academic research around Diagnostics in Florida — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 211 papers.
- University of Florida54
- Mayo Clinic in Florida53
- Florida International University21
- University of South Florida19
- Florida College17
- Liquid biopsy1→5
- Point-of-care testing3→7
- Point of care3→4
- Liquid biopsy3→37
- Oncology1→12
- Internal medicine1→10
- Concordance1→7
- Circulating tumor cell3→8
- Point-of-care testing15
- Liquid biopsy14
- Biopsy6
- Point of care6
- Circulating tumor DNA5
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.